| Short Description : | PDE1A Blocking Peptide for STJ502231 is synthetically produced from the 51-101 sequence and is suitable for use in western blot applications. |
| Applications: | Immunodepletion/Immunocompetition |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Formulation: | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen: | Synthetic peptide corresponding to unique amino acid sequence within amino acid region 51-101 on PDE1A protein. Common to all PDE1A variants. |
| Immunogen Region: | 51-101 |
| Specificity: | This blocking peptide is recommended for use in combination with PDE1A antibody, STJ502231 |
| Background | Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP. |
Information sourced from Uniprot.org